{"pageContent": "Almost 90% of patients with metastatic castration-resistant prostate cancer have a clinically actionable genetic alteration, according to a recently published study. Among these patients, researchers found that 65% had genetic changes that could be targeted by investigational or FDA-approved drugs currently used for other cancers, leading to new individualized treatment strategies.", "metaData": {"source": "Physical activity and its mechanistic effects on prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/25800589/"}}